Alligator Bioscience AB: Year-end Report January-December 2020
Continued focus on clinical development. “Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with metastatic cancer. The results show a promising safety profile with only minor drug-related side effects.” Per Norlén, CEO Alligator Bioscience SIGNIFICANT EVENTS OCTOBER-DECEMBERMitazalimab:• New preclinical comparative data showed that mitazalimab has highly competitive immunostimulatory characteristics.• IND approved for forthcoming clinical studies in the US.• CTA submitted for launch of the forthcoming Phase II study in